Physician profile
Jordan Heller
NPI 1548831688
$4,437.96
in general payments reported to CMS, 2019-2025
30 companies · $1,988 in 2025
The $1,988 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $247 · 2022: $440 · 2023: $803 · 2024: $960 · 2025: $1,988.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,696 · Education: $54.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,696.40 |
| Education | $54.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $655.64 | 2021-2025 | Bimzelx, Cimzia |
| Astrazeneca Pharmaceuticals LP | $452.73 | 2021-2025 | Saphnelo, Fasenra, Tezspire |
| Alexion Pharmaceuticals, INC. | $432.81 | 2023-2025 | Strensiq, Ultomiris |
| Abbvie INC. | $421.65 | 2021-2025 | |
| Amgen INC. | $369.07 | 2021-2025 | Otezla, Krystexxa, Tavneos |
| Janssen Biotech, INC. | $285.32 | 2024-2025 | Tremfya, Simponi Aria |
| Blueprint Medicines Corporation | $216.48 | 2023-2024 | Ayvakit |
| Mallinckrodt Hospital Products INC. | $158.86 | 2023-2025 | Acthar |
| Glaxosmithkline, LLC. | $157.05 | 2023-2025 | Benlysta, Nucala |
| Mylan Specialty L.P. | $147.15 | 2021-2024 | Yupelri |
| E.R. Squibb & Sons, L.L.C. | $133.51 | 2022-2025 | Orencia |
| Novartis Pharmaceuticals Corporation | $123.52 | 2021-2025 | |
| Actelion Pharmaceuticals US, INC. | $99.30 | 2024-2025 | Opsumit, Uptravi |
| Genzyme Corporation | $92.23 | 2023-2024 | |
| Sobi, INC | $91.89 | 2022-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $83.80 | 2022-2025 | Purified Cortrophin Gel |
| Takeda Pharmaceuticals U.S.A., INC. | $61.53 | 2021-2025 | Cuvitru, Takhzyro |
| Organon LLC | $61.43 | 2025 | Hadlima, Renflexis |
| Aurinia Pharma U.S., INC. | $55.15 | 2024-2025 | Lupkynis |
| Pfizer INC. | $52.02 | 2023-2025 | |
| Tersera Therapeutics LLC | $44.98 | 2025 | Quzyttir |
| Tactile Systems Technology INC | $42.74 | 2024 | Flexitouch Plus, Entre Plus |
| Mylan Institutional INC. | $38.19 | 2023 | Hulio |
| Sandoz INC. | $34.65 | 2024-2025 | Hyrimoz |
| Regeneron Healthcare Solutions, INC. | $31.56 | 2022-2024 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.37 | 2023 | Ofev |
| Bayer Healthcare Pharmaceuticals INC. | $22.59 | 2021 | |
| Radius Health, INC. | $17.97 | 2025 | Tymlos |
| Incyte Corporation | $14.91 | 2023 | Opzelura |
| Alk-Abello, INC | $12.86 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jordan Heller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.